Bank of America
ALZN icon

Bank of America’s Alzamend Neuro ALZN Stock Holding History

Bank of America’s Portfolio ALZN Stock Details ALZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-43
Closed -$78 – 5740
2025
Q4 		$78 Buy
43
+6
+16% +$14 ﹤0.01% 6870
2025
Q3 		$88 Buy
37
+18
+95% +$47 ﹤0.01% 7889
2025
Q2 		$55 Buy
19
+3
+19% +$15 ﹤0.01% 8079
2025
Q1 		$139 Buy
16
+1
+7% +$9 ﹤0.01% 7764
2024
Q4 		$158 Buy
15
+3
+25% +$39 ﹤0.01% 7642
2024
Q3 		$177 Buy
12
+11
+1,100% +$288 ﹤0.01% 7600
2024
Q2 		$38 Buy
+1
New +$57 ﹤0.01% 7893
2024
Q1 		– Sell
-1
Closed -$42 – 7703
2023
Q4 		$42 Buy
+1
New +$164 ﹤0.01% 7524
2023
Q2 		– Hold
0
– -$112 – 7690
2023
Q1 		– Hold
0
– – – 7478
2022
Q4 		– Sell
-1
Closed -$1.45K – 7567
2022
Q3 		$2K Hold
1
– – ﹤0.01% 7551
2022
Q2 		$1K Sell
1
-20
-95% -$25.9K ﹤0.01% 7841
2022
Q1 		$35K Buy
+21
New +$39.4K ﹤0.01% 7306

Other funds holding ALZN

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CA
Clearstead Advisors Cleveland, Ohio $10.6B AUM 24.87% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Bank of America's ALZN Position: Q1 2026 in Review

Bank of America sold out of Alzamend Neuro (ALZN) in Q1 2026, closing a stake of 43 shares — an estimated $78 sold.

Bank of America first reported a position in ALZN in Q1 2022 and held it in 11 quarters. The position peaked at $35K in Q1 2022. 12 funds tracked by Wall St. Rank hold ALZN as of Q1 2026.

  • Bank of America reported no remaining Alzamend Neuro position as of Q1 2026 after selling out during the quarter.
  • Bank of America sold 43 Alzamend Neuro shares in Q1 2026, an estimated $78.
  • Bank of America first reported a position in Alzamend Neuro in Q1 2022 and held it in 11 quarters.
  • Bank of America's Alzamend Neuro position peaked at $35K in Q1 2022.
  • 12 funds tracked by Wall St. Rank held Alzamend Neuro as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.